Friends! In this video, I'm going to do an analysis of Celsius Stock, ELF Stock, and CMG Stock
3 extracted signals · 3 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 11 Nov 2025, 00:53 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The video discusses three stocks, CELH, ELF and CMG, trading near their 52-week lows. CELH, currently priced at $41.52, has experienced a 35% drop over the last month. The video identifies concerns about CELH's Alani Nu distribution agreement affecting revenues in the next 1-2 quarters, plus organic growth in the CELH brand only at 13% year-over-year. International growth has only grown 24%. It also mentions analyst concerns, but notes the valuation is more interesting now. For ELF, it trades at $73.74, a 40% drop over 2-3 days. It beat earnings per share expectations, despite slight miss on revenue. Guidance was disappointing due to China tariffs. Rhode acquisition should contribute 13% revenue growth forecast. The company expects sequentially gross margin improvements in the second half of the year. Rhode's expected contribution, analyst is less optimistic. ELFs organic is 3-4% currently. The CEO expects revenue of 1.55 billion to 1.57 billion. The stock needs Rhodes acquisition to hit growth for the quarters ahead. For Chipotle, it trades at $30.59 a 50% decline year to date. It slightly missed revenue and the company said consumer spending is impacting it because of spending less. They won't be doing discouting but will have menu innovation. But its core earnings is still good. Finally, the author notes that the given advice isn't financial.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
3 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.